A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report

Ciurescu,Ioana Adriana; Lencioni,Riccardo; Stemmer,Salomon M.; Farbstein,Motti; Harpaz,Zivit; Bareket-Samish,Avital; Silverman,Michael H.; Fishman,Pnina

doi:10.3892/etm.2024.12551

A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report

Authors:
- Ioana Adriana Ciurescu
- Riccardo Lencioni
- Salomon M. Stemmer
- Motti Farbstein
- Zivit Harpaz
- Avital Bareket-Samish
- Michael H. Silverman
- Pnina Fishman
View Affiliations

Affiliations: Department of Medical Oncology, S.C. Pelican Impex SRL, Oradea 410450, Romania, Department of Radiology, Pisa University School of Medicine, I-56126 Pisa, Italy, Rabin Medical Center, Petah Tikva 4941492, Israel, Can-Fite BioPharma Ltd., Petah Tikva 49170, Israel, BioInsight Ltd., Binyamina 3056814, Israel
Published online on: April 24, 2024 https://doi.org/10.3892/etm.2024.12551
Article Number: 263
Copyright: © Ciurescu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Established treatments for advanced hepatocellular carcinoma (HCC) with Child‑Pugh cirrhosis B (CPB, moderate hepatic dysfunction) are lacking. A recently published randomized phase 2 study in CPB HCC investigating the safety and efficacy of namodenoson (25 mg BID), an A3 adenosine‑receptor agonist vs. placebo, suggested a favorable safety profile and a positive efficacy signal in patients with HCC with a CPB score of 7 (CPB7). The present study reports a 61‑year‑old woman with CPB7 HCC who received namodenoson for over 6 years through this study and its open‑label extension. Computed tomography scans demonstrated partial and complete responses after 7 weeks and 4 years of treatment, respectively. Low albumin levels (31 g/l) and elevated baseline levels of alanine transaminase and aspartate aminotransferase (68 U/l and 44 U/l, respectively) were reported. After 4 weeks of treatment, these levels normalized and were stable for over 6 years. No treatment‑emergent adverse events were noted. At the time of reporting, the response is ongoing as manifested by imaging studies and liver function evaluation.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA and Soerjomataram I: Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 77:1598–1606. 2022.PubMed/NCBI View Article : Google Scholar
3	Ramadori G, Schleyer E and Armbrust T: Safety of imatinib in patients with liver cirrhosis and hepatocellular carcinoma. J Clin Oncol. 22:4244. 2004.
4	Shannon AH, Ruff SM and Pawlik TM: Expert insights on current treatments for hepatocellular carcinoma: Clinical and molecular approaches and bottlenecks to progress. J Hepatocell Carcinoma. 9:1247–1261. 2022.PubMed/NCBI View Article : Google Scholar
5	Tsoris A and Marlar CA: Use of the child Pugh score in liver disease. In: StatPearls. Treasure Island (FL), 2021.
6	Granito A and Bolondi L: Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 18:e101–e112. 2017.PubMed/NCBI View Article : Google Scholar
7	Sorafenib (package insert). Whippany, NJ: Bayer Health Care Pharmaceuticals Inc; 2017.
8	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.PubMed/NCBI View Article : Google Scholar
9	Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008.PubMed/NCBI View Article : Google Scholar
10	Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L and Fishman P: The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 33:287–295. 2008.PubMed/NCBI
11	Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA and Fishman P: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 226:2438–2447. 2011.PubMed/NCBI View Article : Google Scholar
12	Harish A, Hohana G, Fishman P, Arnon O and Bar-Yehuda S: A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol. 23:1245–1249. 2003.PubMed/NCBI
13	Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, et al: CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study. Oncologist. 18:25–26. 2013.PubMed/NCBI View Article : Google Scholar
14	Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, et al: Namodenoson in advanced hepatocellular carcinoma and Child-Pugh B cirrhosis: Randomized placebo-controlled clinical trial. Cancers (Basel). 13(187)2021.PubMed/NCBI View Article : Google Scholar
15	Fishman P, Stemmer SM, Bareket-Samish A, Silverman MH and Kerns WD: Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: Anti-cancer and hepatoprotective effects. Purinergic Signal. 19:513–522. 2023.PubMed/NCBI View Article : Google Scholar
16	Shah RR, Morganroth J and Shah DR: Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives. Drug Saf. 36:491–503. 2013.PubMed/NCBI View Article : Google Scholar
17	National Library of Medicine (NLM): Description of the ‘Namodenoson in the treatment of advanced hepatocellular carcinoma in patients with Child-Pugh Class B7 cirrhosis (LIVERATION)’ study (NCT05201404). Clinical Trials.gov ID, NCT05201404. NLM, Bethesda, MD, 2023. https://clinicaltrials.gov/study/NCT05201404?intr=namodenoson&rank=2&tab=table. Accessed February 20, 2024.